That pesky (corporate owned) MSM.
http://www.inloughborough.com/news/096969/... World-first swine-flu vaccine trial reveals one dose provides 'strong immune response'
Posted on 03/09/09
University of LeicesterResults from the first swine-flu vaccine trials taking place in Leicester reveal a strong immune response after just one dose.
The pilot study, run by the University of Leicester and Leicester Hospitals, was trialled with 100 healthy volunteers, aged between 18 and 50.
Dr Iain Stephenson, who led the trial at the Leicester Royal Infirmary, said: The clinical trial of Novartis MF59-adjuvanted cell-based A (H1N1) vaccine indicates that the swine flu vaccine elicits a strong immune response and is well-tolerated.
http://www.astrazeneca.com/media/latest-pr... 06 January 2009
MedImmune Submits Marketing Authorisation Application in European Union for Intranasal Vaccine to Prevent Seasonal Influenza
AstraZenecaAbout LAIV
Each dose of LAIV is formulated to contain three live attenuated influenza virus strains, which are weakened as to not cause illness: Two Type A influenza strains (A/H1N1 and A/H3N2) and one Type B strain. The vaccine strains are selected annually by the World Health Organization (WHO) based on anticipated circulating influenza strains for the upcoming season. The vaccine is sprayed into the nose, rather than by injection as with other licensed influenza vaccines, where it induces protective immunity.
In the U.S., LAIV is marketed under the trade name FluMistŪ (Influenza Virus Vaccine Live, Intranasal). It was approved by the U.S. Food and Drug Administration in 2003. The vaccine included in the MAA has not been registered in the European Union and is not available outside of the United States.
